Merck, Moderna mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk

Pharmaceutical companies Merck and Moderna announced on August 19, 2026, that a personalized mRNA vaccine they developed significantly reduced the risk of skin cancer returning in a late-stage clinical trial, marking a potential turning point in cancer treatment.